Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Recent Advances in SARS-CoV-2 Main Protease Inhibitors: From Nirmatrelvir to Future Perspectives
Andrea Citarella, Alessandro Dimasi, Davide Moi, et al.
Biomolecules (2023) Vol. 13, Iss. 9, pp. 1339-1339
Open Access | Times Cited: 20

Showing 20 citing articles:

The Design, Synthesis and Mechanism of Action of Paxlovid, a Protease Inhibitor Drug Combination for the Treatment of COVID-19
Miklós Bege, Anikó Borbás
Pharmaceutics (2024) Vol. 16, Iss. 2, pp. 217-217
Open Access | Times Cited: 10
Design, synthesis, and biological evaluation of first-in-class indomethacin-based PROTACs degrading SARS-CoV-2 main protease and with broad-spectrum antiviral activity
Jenny Desantis, Alessandro Bazzacco, Michela Eleuteri, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116202-116202
Open Access | Times Cited: 8
Mechanistic Insights into Nitrile and Alkyne Covalent Inhibitors of the SARS-CoV-2 Main Protease
Ashim Nandi, Mojgan Asadi, Aoxuan Zhang, et al.
ACS Catalysis (2025), pp. 1158-1169
Closed Access
SARS-CoV-2 Mpro oligomerization as a potential target for therapy
Kinga Lis, Jacek Plewka, Filipe Menezes, et al.
International Journal of Biological Macromolecules (2024) Vol. 267, pp. 131392-131392
Open Access | Times Cited: 5
Non-peptidic inhibitors targeting SARS-CoV-2 main protease: A review
Ya-Qi Xiao, Jiao Long, Shuang‐Shuang Zhang, et al.
Bioorganic Chemistry (2024) Vol. 147, pp. 107380-107380
Closed Access | Times Cited: 5
Design, Synthesis, and Biological Evaluation of Trisubstituted Piperazine Derivatives as Noncovalent Severe Acute Respiratory Syndrome Coronavirus 2 Main Protease Inhibitors with Improved Antiviral Activity and Favorable Druggability
Shenghua Gao, Letian Song, Katharina Sylvester, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 23, pp. 16426-16440
Closed Access | Times Cited: 11
Docking and other computing tools in drug design against SARS-CoV-2
А.В. Сулимов, Ivan Ilin, Anna Tashchilova, et al.
SAR and QSAR in environmental research (2024) Vol. 35, Iss. 2, pp. 91-136
Closed Access | Times Cited: 3
Isolation, Virtual Screening, and Evaluation of Hazelnut-Derived Immunoactive Peptides for the Inhibition of SARS-CoV-2 Main Protease
Xiaoting Liu, Shuo Sun, Jiale Liu, et al.
Journal of Agricultural and Food Chemistry (2024) Vol. 72, Iss. 20, pp. 11561-11576
Closed Access | Times Cited: 2
Exploiting high-energy hydration sites for the discovery of potent peptide aldehyde inhibitors of the SARS-CoV-2 main protease with cellular antiviral activity
Daniel W. Carney, Abba E. Leffler, Jeffrey A. Bell, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 103, pp. 117577-117577
Open Access | Times Cited: 1
Targeting Viral and Cellular Cysteine Proteases for Treatment of New Variants of SARS-CoV-2
Davide Gentile, Lucia Chiummiento, Alessandro Santarsiere, et al.
Viruses (2024) Vol. 16, Iss. 3, pp. 338-338
Open Access | Times Cited: 1
Synthesis, SARS-CoV-2 main protease inhibition, molecular docking and in silico ADME studies of furanochromene-quinoline hydrazone derivatives
Blake M. Shellenberger, Olivia N. Basile, Joel Cassel, et al.
Bioorganic & Medicinal Chemistry Letters (2024) Vol. 102, pp. 129679-129679
Closed Access | Times Cited: 1
Identification of Dual Inhibitors Targeting Main Protease (Mpro) and Cathepsin L as Potential Anti-SARS-CoV-2 Agents
Santo Previti, Roberta Ettari, Elsa Calcaterra, et al.
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 5, pp. 602-609
Closed Access | Times Cited: 1
Exploring the Antiviral Potential of Esters of Cinnamic Acids with Quercetin
Valeria Manca, Annalisa Chianese, Vanessa Palmas, et al.
Viruses (2024) Vol. 16, Iss. 5, pp. 665-665
Open Access | Times Cited: 1
New techniques and strategies in drug discovery (2020–2024 update)
Qijie Gong, Jian Song, Yihui Song, et al.
Chinese Chemical Letters (2024), pp. 110456-110456
Closed Access | Times Cited: 1
An Integrated In Silico and In Vitro Approach for the Identification of Natural Products Active against SARS-CoV-2
Rosamaria Pennisi, Davide Gentile, Antonio Rescifina, et al.
Biomolecules (2023) Vol. 14, Iss. 1, pp. 43-43
Open Access | Times Cited: 3
Development of the Novel Nsp16 Inhibitors as Potential Anti-SARS-CoV-2 Agents
Kuojun Zhang, А.В. Сулимов, Ivan Ilin, et al.
Supercomputing Frontiers and Innovations (2024) Vol. 11, Iss. 1
Open Access
Rational Design of Macrocyclic Noncovalent Inhibitors of SARS-CoV-2 Mpro from a DNA-Encoded Chemical Library Screening Hit That Demonstrate Potent Inhibition against Pan-Coronavirus Homologues and Nirmatrelvir-Resistant Variants
Xu Wang, Dimitar Gotchev, Kristi Fan, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 21, pp. 19623-19667
Closed Access
Discovery of peptidomimetic spiropyrrolidine derivatives as novel 3CLpro inhibitors against SARS-CoV-2
Samuel Desta Guma, Zhaoyin Zhou, Kang Song, et al.
European Journal of Medicinal Chemistry (2024) Vol. 281, pp. 117004-117004
Closed Access
ClickGen: Directed exploration of synthesizable chemical space via modular reactions and reinforcement learning
Mingyang Wang, Shuai Li, Jike Wang, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access
Discovery of α-Ketoamide inhibitors of SARS-CoV-2 main protease derived from quaternized P1 groups
Qiao Huang, Baoxue Quan, Yan Chen, et al.
Bioorganic Chemistry (2023) Vol. 143, pp. 107001-107001
Closed Access | Times Cited: 1
Page 1

Scroll to top